Towards immunotherapy of pancreatic cancer.
作者信息
McKenzie I F, Apostolopoulos V
机构信息
The Austin Research Institute Studley Rd Heidelberg, VIC 3084 Australia Email:
出版信息
Gut. 1999 Jun;44(6):767-9. doi: 10.1136/gut.44.6.767.
Abstract
摘要
相似文献
1
Towards immunotherapy of pancreatic cancer.迈向胰腺癌的免疫疗法。
Gut. 1999 Jun;44(6):767-9. doi: 10.1136/gut.44.6.767.
2
Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.恒定链对人乳腺癌细胞系上主要组织相容性复合体I类分子表达及稳定性的影响。
Cancer Immunol Immunother. 2009 May;58(5):729-36. doi: 10.1007/s00262-008-0595-1. Epub 2008 Oct 1.
3
The immunoinformatics of cancer immunotherapy.癌症免疫治疗的免疫信息学
Tissue Antigens. 2007 Oct;70(4):265-71. doi: 10.1111/j.1399-0039.2007.00914.x.
4
5
Dendritic cell maturation and generation of immune responses.树突状细胞成熟与免疫反应的产生。
Haematologica. 1999 Jun;84 Suppl EHA-4:23-5.
6
T cell responses against mutant ras: a basis for novel cancer vaccines.针对突变型ras的T细胞反应：新型癌症疫苗的基础。
Immunotechnology. 1996 Feb;2(1):3-9. doi: 10.1016/1380-2933(95)00028-3.
7
Dendritic cell-tumor cell hybrids and immunotherapy: what's next?树突状细胞-肿瘤细胞杂交瘤与免疫治疗：下一步是什么？
Cytotherapy. 2011 Aug;13(7):774-85. doi: 10.3109/14653249.2011.553593. Epub 2011 Feb 7.
8
Immunotherapy: natural versus synthetic peptides.免疫疗法：天然肽与合成肽
Immunol Today. 1998 Feb;19(2):98.
9
[Cellular immunotherapy for brain tumors].
Nihon Rinsho. 2005 Sep;63 Suppl 9:546-50.
10
[Antitumor cellular immunotherapy: the breakthrough of dendritic cells].[抗肿瘤细胞免疫疗法：树突状细胞的突破]
Bull Cancer. 2000 Jan;87(1):107-15.
引用本文的文献
1
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells.甘露聚糖衍生物可诱导小鼠树突状细胞的表型和功能成熟。
Immunology. 2006 Jul;118(3):372-83. doi: 10.1111/j.1365-2567.2006.02384.x.
2
T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy?T细胞对胰腺癌细胞的黏附与细胞溶解作用：E-钙黏蛋白在免疫治疗中的作用？
Br J Cancer. 2002 Oct 21;87(9):1034-41. doi: 10.1038/sj.bjc.6600597.
本文引用的文献
1
2
Antigen-presenting function of mouse CD1: one molecule with two different kinds of antigenic ligands.
Immunol Rev. 1998 Jun;163:139-50. doi: 10.1111/j.1600-065x.1998.tb01193.x.
3
Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules.抗MUC1抗体直接与由I类H2和HLA分子呈递的MUC1肽发生反应。
J Immunol. 1998 Jul 15;161(2):767-75.
4
Targeting p53 for adoptive T-cell immunotherapy.靶向p53进行过继性T细胞免疫治疗。
Cancer Res. 1998 Jun 15;58(12):2601-5.
5
Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells.用树突状细胞与癌细胞融合体免疫的MUC1转基因小鼠中对人MUC1抗原耐受性的逆转
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6279-83. doi: 10.1073/pnas.95.11.6279.
6
Expression of pancreatitis-associated protein (PAP) mRNA in gastrointestinal cancers.胰腺炎相关蛋白（PAP）mRNA在胃肠道癌中的表达
Int J Pancreatol. 1998 Feb;23(1):11-6. doi: 10.1007/BF02787498.
7
MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral.人类中与MUC1交叉反应的α(1,3)半乳糖抗体将免疫反应从细胞免疫转换为体液免疫。
Nat Med. 1998 Mar;4(3):315-20. doi: 10.1038/nm0398-315.
8
MUC1 peptide epitopes associated with five different H-2 class I molecules.与五种不同的H-2 I类分子相关的MUC1肽表位。
Eur J Immunol. 1997 Oct;27(10):2579-87. doi: 10.1002/eji.1830271017.
9
Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.肿瘤标志物TUM2-PK血清水平在胰腺癌中的价值。
Anticancer Res. 1997 Jul-Aug;17(4B):3031-3.
10
Zotero 插件